Variables | Death (+) | Death (-) | p value |
---|---|---|---|
No. of patients | 42 (32) | 91 (68) | Â |
Age (y) | 71.4 ± 8.3 | 61.4 ± 10.0 | < 0.01 |
Male | 27 (64) | 50 (55) | 0.31 |
Hypertension | 40 (95) | 85 (93) | 0.67 |
Diabetes mellitus | 23 (55) | 53 (58) | 0.71 |
Dyslipidemia | 30 (71) | 72 (79) | 0.34 |
Smoking | 16 (38) | 43 (47) | 0.32 |
Previous CV disease | 20 (48) | 32 (35) | 0.17 |
Dose of ESA (U/week) | 9000 (6000-9000) | 9000 (6000-9000) | 0.92 |
Satins | 10 (24) | 20 (22) | 0.81 |
ACEI and/or ARB | 16 (38) | 49 (54) | 0.09 |
SBP (mm Hg) | 153 ± 15 | 156 ± 23 | 0.49 |
DBP (mm Hg) | 77 ± 10 | 81 ± 10 | 0.03 |
Pulse pressure (mm Hg) | 77 ± 12 | 75 ± 18 | 0.55 |
Body mass index (kg/m2) | 20 (17-23) | 21 (19-22) | 0.23 |
Blood urea nitrogen (mg/dL) | 89 (73-102) | 92 (81-114) | 0.09 |
Serum creatinine (mg/dL) | 9.3 (6.9-10.3) | 9.2 (8.0-10.7) | 0.30 |
Up/Ucr | 4.3 (1.9-7.9) | 4.7 (1.9-7.9) | 0.66 |
Serum albumin (g/dL) | 3.1 ± 0.5 | 3.3 ± 0.6 | 0.11 |
Hemoglobin (g/dL) | 8.3 ± 1.3 | 8.2 ± 1.3 | 0.86 |
Ca-P product (mg2/dL2) | 51.2 (42.1-57.5) | 53.7 (44.2-65.3) | 0.18 |
C-reactive protein (mg/dL) | 0.18 (0.07-0.51) | 0.07 (0.04-0.25) | 0.04 |
intact-PTH (pg/mL) | 235 (168-273) | 250 (148-390) | 0.32 |
CCA-IMT (mm) | 0.83 (0.74-1.12) | 0.76 (0.64-0.90) | < 0.01 |
CAP | 32 (76) | 54 (59) | 0.05 |
Calcified plaque | 23 (55) | 23 (25) | < 0.01 |
CAAC | 37 (88) | 57 (63) | < 0.01 |
AAC | 28 (67) | 44 (48) | < 0.05 |
Low ABI | 12 (29) | 9 (10) | < 0.01 |
Duration of follow-up (months) | 29.1 (17.8-48.5) | 53.6 (45.4-67.8) | < 0.01 |